Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPH1188-11
- Development stage
- Discontinued
- Lead developer
- Shanghai Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SPH1188-11 is an investigational small molecule drug developed by Shanghai Pharmaceuticals Holding for the treatment of non-small cell lung cancer (NSCLC). It acts as an epidermal growth factor receptor (EGFR) antagonist, targeting tumors that have progressed after prior anti-cancer therapy. The drug was evaluated in a Phase I clinical trial to assess its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with locally advanced or metastatic NSCLC. The highest development status reached was Phase 1; however, the program has been suspended/withdraw/n and no further clinical development is ongoing[1][2][3].
02
Targets
Beyond the preview
Go deeper on SPH1188-11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPH1188-11.